LAMP1 and glycogen storage disease III: In conclusion, we show here that GHF-201, a LAMP-1-targeting small molecule acting as a general activator of autophagic flux, can partially correct aberrant metabolic, motor, and myopathological phenotypes in the Agl−/− mouse model of GDE deficiency, or GSDIII, a disease implicating a particularly high glycogen burden, causing liver and myofibrillar injury.